- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
Observation Is a Reasonable Alternative to Adjuvant PD-1 Blockade in Stage IIB/IIIC Melanoma
February 18th 2025, 2:00pm
Tara C. Mitchell, MD, discusses considerations and lingering questions regarding pre- and post-operative management strategies in stage IIB/IIIC melanoma.
Dr Oluwole on CRS and Neurotoxicity Beyond 2 Weeks After Axi-Cel Infusion in R/R LBCL
February 17th 2025, 8:39pm
Transplantation and Cellular Therapy Meetings
Olalekan Oluwole, MD, MPH, discusses the incidence and resolution of CRS and neurological events beyond two weeks following axi-cel infusion in relapsed/refractory LBCL.
Dr Garfall on Ide-Cel and Lenalidomide Maintenance in Myeloma After Suboptimal ASCT Response
February 17th 2025, 8:21pm
Transplantation and Cellular Therapy Meetings
Alfred L. Garfall, MD, MS, discusses data for ide-cel and lenalidomide maintenance in multiple myeloma following a suboptimal response to ASCT and lenalidomide.
Piflufolastat F18 Imaging Is Associated With High Clinician Confidence in Prostate Cancer Management
February 17th 2025, 6:04pm
Genitourinary Cancers Symposium (ASCO GU)
Piflufolastat F18 imaging impacted treatment decisions and was associated with clinician confidence in prostate cancer management.
OPTYX Study Offers Preliminary Glance Into Real-World Use of Relugolix in Advanced Prostate Cancer
February 17th 2025, 5:39pm
Genitourinary Cancers Symposium (ASCO GU)
Patients with advanced prostate cancer who initiated treatment with relugolix indicated various treatment preferences and reasons for therapy initiation.
Real-World Relugolix Adherence Rates Are High in Patients on Medicare With Prostate Cancer
February 17th 2025, 5:07pm
Genitourinary Cancers Symposium (ASCO GU)
Adherence rates improved the longer patients with metastatic and nonmetastatic prostate cancer received relugolix for a high overall adherence rate.
Dr Merseburger on Real-World Outcomes With First-Line Axitinib Plus Avelumab in RCC
February 16th 2025, 8:33pm
Genitourinary Cancers Symposium (ASCO GU)
Axel Merseburger, MD, PhD, discusses the real-world efficacy and safety of first-line avelumab plus axitinib in advanced renal cell carcinoma.
Dr Gupta on Updated Data With Enfortumab Vedotin Plus Pembrolizumab in Urothelial Cancer
February 16th 2025, 8:09pm
Genitourinary Cancers Symposium (ASCO GU)
Shilpa Gupta, MD, discusses updated data with enfortumab vedotin plus pembrolizumab in previously untreated urothelial carcinoma.
Ide-Cel Boosts Response in Myeloma With < CR After Upfront Auto-HCT and Lenalidomide Maintenance
February 16th 2025, 6:05pm
Transplantation and Cellular Therapy Meetings
Ide-cel proved feasible and effective in boosting response in patients with myeloma with suboptimal response to standard frontline therapy.
Non-Myeloablative HSCT Regimen Shows Potential for Immune Tolerance in Haploidentical Living Donor Combined Kidney/Hematopoietic Transplant
February 16th 2025, 5:55pm
Transplantation and Cellular Therapy Meetings
Non-myeloablative HSCT with TLI/TBI/ATG conditioning was safe and active in eliciting immune quiescence and tolerance.
FOXP3/Helios Expression in CD4+ Tcons Correlates With T-Cell Activation After Orca-T in Hematologic Malignancies
February 16th 2025, 5:00pm
Transplantation and Cellular Therapy Meetings
CD4-, FOXP3-, and Helios-positive conventional T cells were increased in patients receiving Orca-T vs peripheral blood stem cell grafts.
Drs Al Malki and Auletta on PTCy GVHD Prophylaxis in Patients With HLA-UUMD
February 15th 2025, 9:45pm
Transplantation and Cellular Therapy Meetings
Monzr Al Malki, MD and Jeffery J. Auletta, MD discuss evaluating PTCy-based GVHD prophylaxis in hematologic malignancies.
Tivozanib Elicits Similar PROs With or Without Nivolumab in Advanced Clear Cell RCC
February 15th 2025, 8:15pm
Genitourinary Cancers Symposium (ASCO GU)
No significant differences in PROs were shown between the tivozanib/nivolumab and tivozanib monotherapy arms in patients with advanced clear cell RCC.
Nivolumab Plus Cabozantinib Provides Durable Benefit in First-Line Advanced RCC
February 15th 2025, 7:58pm
Genitourinary Cancers Symposium (ASCO GU)
Nivolumab in combination with cabozantinib displayed a long-term PFS benefit in patients with treatment-naive advanced RCC.
CBM588 Plus Cabozantinib/Nivolumab Shows Early Activity in Metastatic Renal Cell Carcinoma
February 15th 2025, 7:57pm
Genitourinary Cancers Symposium (ASCO GU)
CBM588 plus cabozantinib and nivolumab shows early efficacy in metastatic renal cell carcinoma.
Cabozantinib Plus Nivolumab/Ipilimumab Sustains PFS Benefit in Advanced RCC
February 15th 2025, 7:53pm
Genitourinary Cancers Symposium (ASCO GU)
Efficacy results remained consistent with previous reports in the cabozantinib, nivolumab, and ipilimumab arm for patients with advanced renal cell carcinoma.
Real-World Data Support the Frontline Use of Avelumab Plus Axitinib in Advanced RCC
February 15th 2025, 7:33pm
Genitourinary Cancers Symposium (ASCO GU)
The combination of first-line avelumab and axitinib was effective and safe in a real-world analysis of patients with advanced RCC.
Updated Data Support Axitinib Interruption and Avelumab Maintenance After Response in Advanced RCC
February 15th 2025, 7:26pm
Genitourinary Cancers Symposium (ASCO GU)
Updated results further supported the feasibility of VEGFR TKI interruption and immunotherapy maintenance in advanced renal cell carcinoma.
Perioperative Lenvatinib Plus Pembrolizumab Is Safe and Effective in Advanced ccRCC
February 15th 2025, 7:10pm
Genitourinary Cancers Symposium (ASCO GU)
Neoadjuvant lenvatinib plus pembrolizumab followed by adjuvant pembrolizumab was safe and effective in patients with locally advanced, nonmetastatic ccRCC.
Lenvatinib Plus Belzutifan Demonstrates Antitumor Activity in Advanced ccRCC
February 15th 2025, 7:04pm
Genitourinary Cancers Symposium (ASCO GU)
Greater responses were observed in a cohort of patients with renal cell carcinoma receiving lenvatinib plus belzutifan vs pembrolizumab plus lenvatinib.